(NASDAQ:BCRX), RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year. Dr. Thackray first joined the company as a member […]

(NASDAQ:HUMA), – Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement – – 82 civilian hospitals now have VAC approval to purchase Symvess(TM) – – ECAT approval makes Symvess available to 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals –

(NASDAQ:IMVT), Initiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjogren's disease (SjD), both in June 2025 All other clinical trials in previously announced six-indications remain on track with increased focus on clinical execution Remission data from the batoclimab proof-of-concept study in GD to

(NASDAQ:LEGN), CARVYKTI(R) (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 million CARVYKTI(R) demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaining progression-free for greater-than or equal to5 years Presented other important CARVYKTI(R) and new solid tumor data at ASCO Over 7,500 patients treated to date Cash and cash equivalents, and time

(NASDAQ:ROIV),(NasdaqGM:ROIVW), BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. Brepocitinib VALOR Phase 3 study in dermatomyositis (DM) remains on track for topline data readout in the second half of

(Other OTC:CWPE),(OTC US:CWPE), Katy, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) — CW Petroleum Corp (OTCQB: CWPE) (the “Company” or “CWPE”), a leading provider of Specialty Renewable and Hydrocarbon Motor Fuels, today announces to its investors and future investors that it has reduced its Authorized Shares of Common Stock from 300,000,000 to 150,000,000, a 50% reduction.

(NASDAQ:GTBP), The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts SAN FRANCISCO,

(NASDAQ:BIIB),(NASDAQ:STOK), – Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that address the underlying cause of the disease – CAMBRIDGE, Mass. and

(NASDAQ:CMPX), In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including

(NasdaqGM:KYMR), Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are